These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 36196862)

  • 1. The Consistent Effectiveness and Safety of Macitentan Therapies Across Idiopathic and Congenital Heart Disease-Associated PulmonaryArterial Hypertension: A Single-Center Experience.
    Kaymaz C; Tanyeri S; Tokgöz HC; Akbal ÖY; Karagöz A; Keskin B; Kültürsay B; Hakgör A; Külahçıoğlu Ş; Bayram Z; Efe SÇ; Tanboğa İH; Doğan C; Akbulut M; Özdemir N
    Anatol J Cardiol; 2022 Oct; 26(10):778-787. PubMed ID: 36196862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study.
    Escribano-Subias P; López R; Almenar L; Lázaro M; Forn I; Torrent A; Blanco I; Barberà JA;
    BMC Pulm Med; 2020 Jun; 20(1):154. PubMed ID: 32487059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk Assessment Tool Implementation in Congenital Heart Disease-Associated Pulmonary Arterial Hypertension.
    Yaylalı YT; Yağmur B; Sinan ÜY; Meriç M; Başarıcı İ; Kılıçkıran Avcı B; Şenol H; Nalbantgil S; Küçükoğlu S; Öngen Z
    Anatol J Cardiol; 2023 Aug; 27(8):479-485. PubMed ID: 37288853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment of pulmonary arterial hypertension with macitentan in Japanese patients.
    Tahara N; Dobashi H; Fukuda K; Funauchi M; Hatano M; Ikeda S; Joho S; Kihara Y; Kondo T; Matsushita M; Minamino T; Nakanishi N; Okano Y; Ozaki Y; Saji T; Sakai S; Tanabe N; Watanabe H; Yamada H; Yoshioka K; Hatta M; Sasayama S
    Curr Med Res Opin; 2020 Jun; 36(6):921-928. PubMed ID: 32298185
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of Macitentan in Patients With Eisenmenger Syndrome.
    Gatzoulis MA; Landzberg M; Beghetti M; Berger RM; Efficace M; Gesang S; He J; Papadakis K; Pulido T; Galiè N;
    Circulation; 2019 Jan; 139(1):51-63. PubMed ID: 30586694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.
    Galiè N; Jansa P; Pulido T; Channick RN; Delcroix M; Ghofrani HA; Le Brun FO; Mehta S; Perchenet L; Rubin LJ; Sastry BKS; Simonneau G; Sitbon O; Souza R; Torbicki A
    Eur Heart J; 2017 Apr; 38(15):1147-1155. PubMed ID: 28329315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension: extended study results.
    Aypar E; Alehan D; Karagöz T; Aykan H; Ertugrul İ
    Cardiol Young; 2020 May; 30(5):681-685. PubMed ID: 32290885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension.
    Aypar E; Alehan D; Karagöz T; Aykan HH; Ertugrul İ
    Cardiol Young; 2018 Apr; 28(4):542-547. PubMed ID: 29233198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Dynamics of the clinical functional and hemodynamic profile of patients with pulmonary arterial hypertension with initial monotherapy with endothelin receptor antagonists: bosentan vs. macitentan].
    Martynyuk TV; Aleevskaya AM
    Kardiologiia; 2020 Aug; 60(7):28-35. PubMed ID: 33155938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple vasodilator therapy in pulmonary arterial hypertension associated with congenital heart disease.
    Luna-Lopez R; Segura de la Cal T; Sarnago Cebada F; Martin de Miguel I; Hinojosa W; Cruz-Utrilla A; Velazquez MT; Delgado JF; Mendoza A; Arribas Ynsaurriaga F; Escribano-Subías P
    Heart; 2024 Feb; 110(5):346-352. PubMed ID: 37903556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world effectiveness and safety of macitentan in patients with pulmonary artery hypertension: a multicenter, retrospective, observational study in China.
    Chen YC; Dai HL; Liu CL; Li J; Ji QS; Cao YS; Xiao J; Jian R; Zhuo JM; Luo XC; Gu H
    Curr Med Res Opin; 2024 Sep; 40(9):1455-1464. PubMed ID: 39044676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Experience of Macitentan for Pulmonary Arterial Hypertension in Adult Congenital Heart Disease.
    Herbert S; Gin-Sing W; Howard L; Tulloh RMR
    Heart Lung Circ; 2017 Oct; 26(10):1113-1116. PubMed ID: 28237536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of Patients with Pulmonary Arterial Hypertension Starting Macitentan After the Discontinuation of Other Endothelin-Receptor Antagonists: Results of a Retrospective Study.
    Cadenas-Menéndez S; Álvarez Vega P; Oterino Manzanas A; Alonso Lecue P; Roig Figueroa V; Bedate Díaz P; Ortiz de Saracho J; Cifrián Martínez JM
    Am J Cardiovasc Drugs; 2020 Oct; 20(5):481-487. PubMed ID: 31879844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.
    Chin KM; Rubin LJ; Channick R; Di Scala L; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF
    Circulation; 2019 May; 139(21):2440-2450. PubMed ID: 30982349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis.
    Hoeper MM; Pausch C; Olsson KM; Huscher D; Pittrow D; Grünig E; Staehler G; Vizza CD; Gall H; Distler O; Opitz C; Gibbs JSR; Delcroix M; Ghofrani HA; Ewert R; Kaemmerer H; Kabitz HJ; Skowasch D; Behr J; Milger K; Halank M; Wilkens H; Seyfarth HJ; Held M; Dumitrescu D; Tsangaris I; Vonk-Noordegraaf A; Ulrich S; Klose H; Claussen M; Eisenmann S; Schmidt KH; Rosenkranz S; Lange TJ
    J Heart Lung Transplant; 2022 Jul; 41(7):971-981. PubMed ID: 35430147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of changes in NT-proBNP, hsTnT and uric acid levels with haemodynamic changes after targeted medical therapies in patients with idiopathic pulmonary arterial hypertension.
    Li WT; Wu CW; Liu JM
    Cardiovasc J Afr; 2022 Jan-Feb 23; 33(1):10-14. PubMed ID: 34851353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension.
    Hoeper MM; Pausch C; Olsson KM; Huscher D; Pittrow D; Grünig E; Staehler G; Vizza CD; Gall H; Distler O; Opitz C; Gibbs JSR; Delcroix M; Ghofrani HA; Park DH; Ewert R; Kaemmerer H; Kabitz HJ; Skowasch D; Behr J; Milger K; Halank M; Wilkens H; Seyfarth HJ; Held M; Dumitrescu D; Tsangaris I; Vonk-Noordegraaf A; Ulrich S; Klose H; Claussen M; Lange TJ; Rosenkranz S
    Eur Respir J; 2022 Jul; 60(1):. PubMed ID: 34737226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macitentan in pulmonary hypertension due to left ventricular dysfunction.
    Vachiéry JL; Delcroix M; Al-Hiti H; Efficace M; Hutyra M; Lack G; Papadakis K; Rubin LJ
    Eur Respir J; 2018 Feb; 51(2):. PubMed ID: 29437943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial.
    Sitbon O; Bosch J; Cottreel E; Csonka D; de Groote P; Hoeper MM; Kim NH; Martin N; Savale L; Krowka M
    Lancet Respir Med; 2019 Jul; 7(7):594-604. PubMed ID: 31178422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of a Novel Endothelin Receptor Antagonist, Macitentan, in Japanese Patients With Pulmonary Arterial Hypertension.
    Tahara N; Dobashi H; Fukuda K; Funauchi M; Hatano M; Ikeda S; Joho S; Kihara Y; Kimura T; Kondo T; Matsushita M; Minamino T; Nakanishi N; Ozaki Y; Saji T; Sakai S; Tanabe N; Watanabe H; Yamada H; Yoshioka K; Sasayama S
    Circ J; 2016 May; 80(6):1478-83. PubMed ID: 27180890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.